Back to search results

Vascular Effects of Empagliflozin in Non-diabetic Chronic Kidney Disease

This study is looking at how a medication called empagliflozin affects blood vessels in people with chronic kidney disease (CKD) who do not have diabetes. Empagliflozin is already known to help with CKD and heart failure. Researchers want to see if it can improve blood vessel health and physical function in people with non-diabetic CKD, especially those without a lot of protein in their urine. You might be able to join if you are an adult aged 18 or older with an eGFR (a measure of kidney function) between 20-59 mL/min and albuminuria (protein in urine) less than 300 mg/g. The main goal is to see if empagliflozin improves how well your blood vessels expand, measured by flow-mediated dilation (FMD). The study is currently unclear on its recruitment status.

Study design
This is a randomized, double-blind, placebo-controlled study involving 52 participants. Participants will receive either empagliflozin or a matching placebo.
What's involved
Participants will be treated for 16 weeks. Measurements of endothelium-dependent vasodilation will be taken at baseline, 8 weeks, and 16 weeks.
Compensation
Not stated in the trial record.
Follow-up
Measurements will be taken up to 16 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07060417

Vascular Effects of SGLT2i in Non-diabetic CKD

Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatment
VA Office of Research and Development
~52 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:EmpagliflozinPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in endothelium-dependent vasodilation as measured by flow mediated dilation (FMD)
Measured over baseline, 8 weeks, 16 weeks

Conditions

Non-diabetic Chronic Kidney Disease

Explore related trials

Chronic Kidney Disease

NCT07060417

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utahstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Monique Cho, MD · PRINCIPAL_INVESTIGATOR · VA Salt Lake City Health Care System, Salt Lake City, UT

Who to contact

Monique Cho, MD
[email protected]
(801) 582-1565
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

eGFR (estimated glomerular filtration rate) 20-59 mL/min (milliliters per minute)
albuminuria \<300 mg/g (milligrams per gram)

Exclusion

Type 1 or 2 diabetes mellitus
expected to start dialysis or receive kidney transplantation or die within 4 months
prior therapy with SGLT2i (Sodium-Glucose Co-Transporter 2 inhibitors) within the previous year
unable to participate in the physical function tests (hand grip, walk)
infections requiring intravenous antibiotic treatment
malignancy requiring systemic therapy
extremity skin ulceration requiring active therapy
history of Fournier's gangrene
severe hypoglycemia requiring external assistance within the past one year
known allergy to empagliflozin
pregnancy

What this trial measures

  • Change in endothelium-dependent vasodilation as measured by flow mediated dilation (FMD)baseline, 8 weeks, 16 weeks

    Brachial artery FMD will be used to assess if empagliflozin can improve endothelial function of conduit arteries in the upper limb. Brachial artery FMD outcome will be quantified as the maximal change in brachial artery diameter during the two-minute period after cuff release, expressed as a percentage increase from the pre-occlusion value (%FMD).